in relation to covid-19 vaccines, the mhra has authorised their supply following a rigorous review of their safety, quality and efficacy. the clinical trials of covid-19 vaccines have shown them to be effective and acceptably safe; however, as part of its statutory functions, the mhra is responsible for monitoring these vaccines on an ongoing basis to ensure their benefits continue to outweigh any risks. this weekly report summarises information received via the yellow card scheme and will be published regularly to include other safety investigations carried out by the mhra under the covid-19 vaccine surveillance strategy.
the next publication will be on 16 june 2022 containing data up to 8 june 2022. robust safety monitoring and surveillance will continue to be carried out during this period. we would ask anyone who suspects they have experienced a side effect linked with their covid-19 vaccine to report via the coronavirus yellow card website: https://coronavirus-yellowcard.mhra.gov.uk/. we’ll send you a link to a feedback form.
important: if you are experiencing a medical emergency, seek immediate assistance from a healthcare provider or call 9-1-1. cdc and fda do not provide while very important in monitoring vaccine safety, vaers reports alone cannot be used to determine if a vaccine caused or contributed to an adverse event or to search articles on this page by keyword, first click the “open all” tab to list all publications. then use the “find on this page” function available in, .
the mhra confirmed on that the covid-19 vaccines made by pfizer and astrazeneca can be used as safe and effective booster doses. following please note that over the jubilee bank holiday period the publication date of the coronavirus vaccine – weekly summary of yellow card reporting will differ from openvaers is a private organization that posts publicly available cdc/fda data of injuries reported post-vaccination. reports are not proof of causality., .
When you try to get related information on vaers weekly summary, you may look for related areas. .